Amgen (AMGN) Tops Q3 EPS by 25c, Offers Guidance

Amgen (NASDAQ: AMGN) reported Q3 EPS of $4.70, $0.25 better than the analyst estimate of $4.45. Revenue for the quarter came in at $6.7 billion versus the consensus estimate of $6.58 billion.

GUIDANCE:

Amgen sees FY2022 EPS of $17.25-$17.85, versus the consensus of $17.50. Amgen sees FY2022 revenue of $26-26.3 billion, versus the consensus of $26.14 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• L3Harris CEO steps down amid conduct review, shares drop
• Is Treasury selloff a major issue for stock market bulls?